Biosimilars: Opportunity or Threat?

Part of the challenge in understanding the biosimilars market is finding reliable information you can use to gauge market opportunity or assess the impact of biosimilars on existing and emerging products. DRG’s Biosimilars insights helps fill that information gap.

A different kind of market

Get a better understanding of the role of biosimilars in treatment pathways. Look into the factors that are driving or limiting market uptake. Discover what’s in biosimilar product pipelines in major markets. Learn about strategies companies use to introduce biosimilars – or defend against them.



What does the future look like?

Evaluate current and future market size for biosimilars in the four leading therapy areas: oncology, immunology, endocrinology, and nephrology. With our interactive, brand-level forecasts, you can see how your biosimilar stacks up against existing brands.

What do doctors think?

Use the results of our in-depth surveys of over 540 US and EU physicians across 6 specialties to find out how physicians are currently using biosimilars and what could change their behavior.



DRG forecasts the biosimilars market for more than 30 reference brand biologics, including:

ESAs (erythropoiesis-stimulating agents)
Epoetin alfa (Epogen, Procrit/Eprex, Espo)
Darbepoetin alfa (Aranesp, Nesp)
G-CSFs (granulocyte-colony stimulating factors)
Filgrastim (Neupogen, Gran)
Pegfilgrastim (Neulasta, G-Lasta)
Insulin aspart (NovoLog)
Insulin aspart NPH (NovoMix)
Insulin detemir (Levemir)
Insulin glargine (Lantus)
Insulin lispro (Humalog)
Insulin lispro NPH (Humalog Mix)
FSH (follicle-stimulating hormone)
Follitropin alfa (Gonal-F/Gonalef)
Immune biologics
Abatacept (Orencia)
Adalimumab (Humira)
Etanercept (Enbrel)
Infliximab (Remicade)
Rituximab (Rituxan/ MabThera)
Tocilizumab (Actemra/ RoActemra)
Ustekinumab (Stelara)
hGHs (human growth hormones)
Somatropin (Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen)
Oncology MAbs (monoclonal antibodies)
Bevacizumab (Avastin)
Cetuximab (Erbitux)
Panitumumab (Vectibix)
Rituximab (Rituxan/ MabThera)
Trastuzumab (Herceptin)

Take our test drive